Chemotherapy Regimen for Triple-Positive Breast Cancer

First-Line Treatment Approach

The American Society of Clinical Oncology recommends an anthracycline-taxane sequence combined with HER2-targeted therapy (trastuzumab) and endocrine therapy for triple-positive breast cancer (ER+/PR+/HER2+) 1, 2, 3
Anthracycline-based regimen followed by taxanes is the preferred approach, with sequential administration showing superior outcomes compared to concomitant use 1, 3
Standard regimen consists of 4 cycles of doxorubicin and cyclophosphamide (AC) followed by 4 cycles of a taxane (paclitaxel or docetaxel) 1, 3
Dose-dense schedules (with G-CSF support) should be considered, particularly for highly proliferative tumors 1, 3

Trastuzumab should be administered concurrently with the taxane portion of chemotherapy, not with anthracyclines 1, 4
Trastuzumab should be continued for a total duration of one year 4
The addition of trastuzumab reduces recurrence risk by approximately 50% and improves overall survival 5

Regular cardiac monitoring (every 3-4 months) during trastuzumab treatment is mandatory due to potential cardiotoxicity 4
Baseline cardiac function assessment (LVEF) is required before starting treatment 4
Endocrine therapy should be administered after completion of chemotherapy, not concurrently 1, 2
All patients with ≥1% ER expression should receive appropriate endocrine therapy 2, 5

For node-positive disease, consider dual HER2 blockade with pertuzumab and trastuzumab in the adjuvant setting 6
Benefit of dual blockade is independent of hormone receptor status 6

For stage I HER2+ disease, paclitaxel + trastuzumab is the preferred regimen 6
For higher-risk disease (node-positive or larger tumors), standard anthracycline → taxane sequence with trastuzumab (AC-T+H) or TCH if cardiac concerns exist 1, 6
Consider dual HER2 blockade with pertuzumab for node-positive disease 6
Following chemotherapy and HER2-targeted therapy, add endocrine therapy for all hormone receptor-positive cases 2, 5